THYRAGE is a EC funded H2020 research project that will investigate the effects of thyroid hormone on a wide range of age-related diseases, including osteoporosis, osteoarthritis, neurological disorders and sarcopenia. Knowledge generated in this innovative project is needed to develop new strategies to prevent and treat these diseases in the elderly.

TRUST and IEMO meeting 2019

published: 13-06-2019 15:26
A combined meeting for the TRUST and IEMO-80 plus thyroid trial was organised on the 19th and 20th of May 2019 in Leiden, the Netherlands. THYRAGE investigators Diana van Heemst, Rudi Westendorp (also one of the principal investigators of TRUST) and Nicolien van Vliet were among the attendants.

 

The TRUST (Thyroid Hormone Replacement for Subclinical Hypothyroidism Trial) and IEMO-80 plus thyroid trial are both randomized controlled trials set up in close collaboration to investigate the effects of levothyroxine treatment for subclinical hypothyroidism in older adults. TRUST included individuals aged 65 years and older throughout Scotland, Switzerland, Ireland and the Netherlands. For the IEMO-80 plus thyroid trial individuals were included only in the Netherlands and Switzerland and they had to be 80 years or older. The two trials work together closely to combine forces in investigating outcomes of levothyroxine treatment in this population of older adults with mild thyroid dysfunction. THYRAGE is also involved in these trials by performing laboratory measurements in blood samples taken from participants during the trial which are stored in a biobank.

During the meeting, the first results from measurements in this biobank were presented by Wendy den Elzen (LUMC, the Netherlands) and Nicolien van Vliet. Furthermore, successful publications as well as future plans were discussed among the representatives of all study sites involved.

The meeting was a great success and a follow-up meeting is currently being planned for next year.

More information about the trials:
TRUST trial
IEMO-80 plus thyroid trial

.